These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 21223484)

  • 1. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size.
    Vulpio C; Maresca G; Distasio E; Cacaci S; Panocchia N; Luciani G; Bossola M
    Hemodial Int; 2011 Jan; 15(1):69-78. PubMed ID: 21223484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
    Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
    Jamaluddin EJ; Gafor AH; Yean LC; Cader R; Mohd R; Kong NC; Shah SA
    Clin Exp Nephrol; 2014 Jun; 18(3):507-14. PubMed ID: 23903802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
    Llach F; Yudd M
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
    J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study.
    Koc H; Hoser H; Akdag Y; Kendir C; Ersoy FF
    Int Urol Nephrol; 2019 Jul; 51(7):1261-1270. PubMed ID: 31161518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
    Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients.
    Seeherunvong W; Nwobi O; Abitbol CL; Chandar J; Strauss J; Zilleruelo G
    Pediatr Nephrol; 2006 Oct; 21(10):1434-9. PubMed ID: 16900383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
    Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
    Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study.
    Mittman N; Desiraju B; Meyer KB; Chattopadhyay J; Avram MM
    Kidney Int Suppl; 2010 Aug; (117):S33-6. PubMed ID: 20671742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients.
    Kumar J; Tran NT; Schomberg J; Streja E; Kalantar-Zadeh K; Pahl M
    J Ren Nutr; 2016 Jul; 26(4):265-9. PubMed ID: 27038806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
    Sharma A; Marshall TS; Khan SS; Johns B
    Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
    Ong LM; Narayanan P; Goh HK; Manocha AB; Ghazali A; Omar M; Mohamad S; Goh BL; Shah S; Seman MR; Vaithilingam I; Ghazalli R; Rahmat K; Shaariah W; Ching CH;
    Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Pharmacological Effects of Paricalcitol Versus Calcitriol on Secondary Hyperparathyroidism in the Dialysis Population.
    Večerić-Haler Ž; Romozi K; Antonič M; Benedik M; Ponikvar JB; Ponikvar R; Knap B
    Ther Apher Dial; 2016 Jun; 20(3):261-6. PubMed ID: 27312912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
    Tentori F; Hunt WC; Stidley CA; Rohrscheib MR; Bedrick EJ; Meyer KB; Johnson HK; Zager PG;
    Kidney Int; 2006 Nov; 70(10):1858-65. PubMed ID: 17021609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis.
    Thadhani RI; Rosen S; Ofsthun NJ; Usvyat LA; Dalrymple LS; Maddux FW; Hymes JL
    Clin J Am Soc Nephrol; 2020 Mar; 15(3):384-391. PubMed ID: 32111702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol.
    Cozzolino M; Galassi A; Gallieni M; Brancaccio D
    Curr Vasc Pharmacol; 2008 Apr; 6(2):148-53. PubMed ID: 18393917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.
    Abdul Gafor AH; Saidin R; Loo CY; Mohd R; Zainudin S; Shah SA; Norella KC
    Nephrology (Carlton); 2009 Aug; 14(5):488-92. PubMed ID: 19298641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.